{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T03:43:51Z","timestamp":1774323831798,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shanghai Fengxian District Science and Technology Project","award":["20181704"],"award-info":[{"award-number":["20181704"]}]},{"name":"Shanghai Fengxian District Science and Technology Project","award":["20181704"],"award-info":[{"award-number":["20181704"]}]},{"name":"Shanghai Fengxian District Science and Technology Project","award":["20181704"],"award-info":[{"award-number":["20181704"]}]},{"name":"Shanghai Fengxian District Science and Technology Project","award":["20181704"],"award-info":[{"award-number":["20181704"]}]},{"name":"Shanghai Fengxian District Science and Technology Project","award":["20181704"],"award-info":[{"award-number":["20181704"]}]},{"name":"Shanghai University of Medicine and Health Sciences Seed Foundation","award":["SFP-18-21-15-001"],"award-info":[{"award-number":["SFP-18-21-15-001"]}]},{"name":"Shanghai University of Medicine and Health Sciences Seed Foundation","award":["SFP-18-21-15-001"],"award-info":[{"award-number":["SFP-18-21-15-001"]}]},{"name":"Shanghai University of Medicine and Health Sciences Seed Foundation","award":["SFP-18-21-15-001"],"award-info":[{"award-number":["SFP-18-21-15-001"]}]},{"name":"Shanghai University of Medicine and Health Sciences Seed Foundation","award":["SFP-18-21-15-001"],"award-info":[{"award-number":["SFP-18-21-15-001"]}]},{"name":"Shanghai University of Medicine and Health Sciences Seed Foundation","award":["SFP-18-21-15-001"],"award-info":[{"award-number":["SFP-18-21-15-001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The objective of the present study was to determine the effect of allisartan, a new angiotensin II type 1 receptor antagonist on vascular remodeling through voltage gated potassium channels (Kv7) in hypertensive rats.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p> The study included a total of 47 Sprague Dawley (SD) rats. The animals were randomized to sham operation (<jats:italic>n<\/jats:italic>\u2009=\u200914), untreated hypertensive control group (<jats:italic>n<\/jats:italic>\u2009=\u200918) and allisartan treatment group (<jats:italic>n<\/jats:italic>\u2009=\u200915). Using renal artery stenosis, hypertension was induced in animals. Single dose of allisartan was administered intra-gastrically to animals in the allisartan treatment group and match placebo in the other 2 groups. Wire myography was used to measure the muscle tension in isolated mesenteric arteries from the animals. Real-time polymerase chain reaction was used to quantify the expression of Kv7 channel mRNA subunits.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After 4 weeks of treatment, a significant decrease in mean arterial, systolic and diastolic blood pressure (SBP and DBP) was observed in allisartan treatment group compared to hypertension control group. The median arterial wall thickness and area\/diameter ratio reduced significantly in treatment group compared to untreated hypertension group (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Wire myography demonstrated increased relaxation of mesenteric artery with increase in concentration of ML213. A significant up-regulation in the expression of all Kv7 mRNA subunits was observed in allisartan group compared to untreated hypertension group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>From the results, allisartan was found to lower BP and preserve vascular remodeling through Kv7 channels.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40360-021-00498-7","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T07:05:23Z","timestamp":1623222323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Allisartan ameliorates vascular remodeling through regulation of voltage-gated potassium channels in hypertensive rats"],"prefix":"10.1186","volume":"22","author":[{"given":"Xiaoqin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunfang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"key":"498_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.lfs.2016.02.080","volume":"150","author":"S Kaur","year":"2016","unstructured":"Kaur S, Muthuraman A. Therapeutic evaluation of rutin in two-kidney one-clip model of renovascular hypertension in rat. Life Sci. 2016;150:89\u201394.","journal-title":"Life Sci"},{"key":"498_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.pcad.2019.11.009","volume":"63","author":"M Yildiz","year":"2020","unstructured":"Yildiz M, Oktay AA, Stewart MH, Milani RV, Ventura HO, Lavie CJ. Left ventricular hypertrophy and hypertension. Prog Cardiovasc Dis. 2020;63:10\u201321.","journal-title":"Prog Cardiovasc Dis"},{"key":"498_CR3","doi-asserted-by":"publisher","first-page":"e12423","DOI":"10.1111\/micc.12423","volume":"25","author":"M Nieves-Cintr\u00f3n","year":"2018","unstructured":"Nieves-Cintr\u00f3n M, Syed AU, Nystoriak MA, Navedo MF. Regulation of voltage-gated potassium channels in vascular smooth muscle during hypertension and metabolic disorders. Microcirculation. 2018;25:e12423.","journal-title":"Microcirculation"},{"key":"498_CR4","doi-asserted-by":"publisher","first-page":"H1284","DOI":"10.1152\/ajpheart.01053.2004","volume":"289","author":"IN Bratz","year":"2005","unstructured":"Bratz IN, Swafford AN, Kanagy NL, Dick GM. Reduced functional expression of K + channels in vascular smooth muscle cells from rats made hypertensive with N\u03c9 -nitro- l -arginine. Am J Physiol-Heart Circ Physiol. 2005;289:H1284\u201390.","journal-title":"Am J Physiol-Heart Circ Physiol"},{"key":"498_CR5","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/S0895-7061(01)02145-8","volume":"14","author":"R Cox","year":"2001","unstructured":"Cox R. Differences in K + current components in mesenteric artery myocytes from WKY and SHR. Am J Hypertens. 2001;14:897\u2013907.","journal-title":"Am J Hypertens"},{"key":"498_CR6","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/S0895-7061(96)00179-3","volume":"9","author":"R Cox","year":"1996","unstructured":"Cox R. Comparison of K + channel properties in freshly isolated myocytes from thoracic aorta of WKY and SHR. Am J Hypertens. 1996;9:884\u201394.","journal-title":"Am J Hypertens"},{"key":"498_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1113\/jphysiol.2008.165217","volume":"587","author":"A Moreno-Dom\u00ednguez","year":"2009","unstructured":"Moreno-Dom\u00ednguez A, Cidad P, Miguel-Velado E, L\u00f3pez-L\u00f3pez JR, P\u00e9rez-Garc\u00eda MT. De novo expression of Kv6.3 contributes to changes in vascular smooth muscle cell excitability in a hypertensive mice strain: Kv channels in vascular smooth muscle. J Physiol. 2009;587:625\u201340.","journal-title":"J Physiol"},{"key":"498_CR8","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1161\/HYPERTENSIONAHA.113.01244","volume":"62","author":"S Khanamiri","year":"2013","unstructured":"Khanamiri S, Soltysinska E, Jepps TA, Bentzen BH, Chadha PS, Schmitt N, et al. Contribution of K v 7 Channels to Basal Coronary Flow and Active Response to Ischemia. Hypertension. 2013;62:1090\u20137.","journal-title":"Hypertension"},{"key":"498_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fcvm.2017.00075","volume":"4","author":"AL Fosmo","year":"2017","unstructured":"Fosmo AL, Skraastad \u00d8B. The Kv7 Channel and Cardiovascular Risk Factors. Front Cardiovasc Med. 2017;4:75.","journal-title":"Front Cardiovasc Med"},{"key":"498_CR10","doi-asserted-by":"publisher","unstructured":"Zhu Y-R, Jiang X-X, Ye P, Chen S, Zhang D-M. Potassium Channels in the Vascular Diseases. In: Gonz\u00e1lez M, editor. Vascular Biology - Selection of Mechanisms and Clinical Applications. IntechOpen; 2020. doi:https:\/\/doi.org\/10.5772\/intechopen.82474.","DOI":"10.5772\/intechopen.82474"},{"key":"498_CR11","doi-asserted-by":"publisher","first-page":"R1001-1018","DOI":"10.1152\/ajpregu.90960.2008","volume":"296","author":"B Ponnuchamy","year":"2009","unstructured":"Ponnuchamy B, Khalil RA. Cellular mediators of renal vascular dysfunction in hypertension. Am J Physiol Regul Integr Comp Physiol. 2009;296:R1001-1018.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"498_CR12","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/01.RES.62.4.749","volume":"62","author":"AA Geisterfer","year":"1988","unstructured":"Geisterfer AA, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res. 1988;62:749\u201356.","journal-title":"Circ Res"},{"key":"498_CR13","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1161\/01.RES.74.6.1141","volume":"74","author":"KK Griendling","year":"1994","unstructured":"Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141\u20138.","journal-title":"Circ Res"},{"key":"498_CR14","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1161\/01.ATV.19.8.1843","volume":"19","author":"CM Ford","year":"1999","unstructured":"Ford CM, Li S, Pickering JG. Angiotensin II stimulates collagen synthesis in human vascular smooth muscle cells. Involvement of the AT(1) receptor, transforming growth factor-beta, and tyrosine phosphorylation. Arterioscler Thromb Vasc Biol. 1999;19:1843\u201351.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"498_CR15","doi-asserted-by":"publisher","first-page":"e14907","DOI":"10.1097\/MD.0000000000014907","volume":"98","author":"J-Q Zhang","year":"2019","unstructured":"Zhang J-Q, Yang G-H, Zhou X, Liu J-X, Shi R, Dong Y, et al. Effects of allisartan isoproxil on blood pressure and target organ injury in patients with mild to moderate essential hypertension: Medicine (Baltimore). 2019;98:e14907.","journal-title":"Medicine (Baltimore)"},{"key":"498_CR16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/aps.2009.11","volume":"30","author":"M Wu","year":"2009","unstructured":"Wu M, Ma X, Yang C, Tao X, Liu A, Su D, et al. Effects of allisartan, a new AT1 receptor blocker, on blood pressure and end-organ damage in hypertensive animals. Acta Pharmacol Sin. 2009;30:307\u201313.","journal-title":"Acta Pharmacol Sin"},{"key":"498_CR17","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/hr.2011.114","volume":"34","author":"H Hasegawa","year":"2011","unstructured":"Hasegawa H, Takano H, Narumi H, Ohtsuka M, Mizuguchi T, Namiki T, et al. Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients. Hypertens Res. 2011;34:1179\u201384.","journal-title":"Hypertens Res"},{"issue":"Suppl 3","key":"498_CR18","doi-asserted-by":"publisher","first-page":"S224-229","DOI":"10.1097\/01.ASN.0000032544.37147.AE","volume":"13","author":"G Deferrari","year":"2002","unstructured":"Deferrari G, Ravera M, Deferrari L, Vettoretti S, Ratto E, Parodi D. Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers. J Am Soc Nephrol JASN. 2002;13 Suppl 3:S224-229.","journal-title":"J Am Soc Nephrol JASN"},{"key":"498_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ijcard.2008.11.017","volume":"140","author":"KK Koh","year":"2010","unstructured":"Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Koh Y, et al. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol. 2010;140:73\u201381.","journal-title":"Int J Cardiol"},{"key":"498_CR20","doi-asserted-by":"publisher","first-page":"e90217","DOI":"10.1371\/journal.pone.0090217","volume":"9","author":"S Li","year":"2014","unstructured":"Li S, Wu Y, Yu G, Xia Q, Xu Y. Angiotensin II receptor blockers improve peripheral endothelial function: a meta-analysis of randomized controlled trials. PloS One. 2014;9:e90217.","journal-title":"PloS One"},{"key":"498_CR21","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1007\/s12325-020-01413-y","volume":"37","author":"G Zhang","year":"2020","unstructured":"Zhang G, Fan Y, Qiu Y, Zhou Z, Zhang J, Wang Z, et al. Allisartan Isoproxil improves Endothelial function and vascular damage in patients with essential hypertension: a single-center, open-label, randomized controlled trial. Adv Ther. 2020;37:3551\u201361.","journal-title":"Adv Ther"},{"key":"498_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000047275","volume":"89","author":"B Waeber","year":"1998","unstructured":"Waeber B. Potential Cardioprotective Effect of Mibefradil in the Long-Term Treatment of Hypertension. Cardiology. 1998;89:16\u201322.","journal-title":"Cardiology"},{"key":"498_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/ajh\/6.1.28","volume":"6","author":"K Tsunoda","year":"1993","unstructured":"Tsunoda K, Abe K, Hagino T, Omata K, Misawa S, Imai Y, et al. Hypotensive Effect of Losartan, a Nonpeptide Angiotensin II Receptor Antagonist, in Essential Hypertension. Am J Hypertens. 1993;6:28\u201332.","journal-title":"Am J Hypertens"},{"key":"498_CR24","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2165\/00003088-200544080-00003","volume":"44","author":"DA Sica","year":"2005","unstructured":"Sica DA, Gehr TWB, Ghosh S. Clinical Pharmacokinetics of Losartan. Clin Pharmacokinet. 2005;44:797\u2013814.","journal-title":"Clin Pharmacokinet"},{"key":"498_CR25","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2165\/00044011-200424100-00008","volume":"24","author":"H Amini","year":"2004","unstructured":"Amini H, Ahmadiani A, Moazenzadeh M. Pharmacokinetics of losartan and its active metabolite EXP3174 in healthy Iranian subjects. Clin Drug Investig. 2004;24:619\u201323.","journal-title":"Clin Drug Investig"},{"key":"498_CR26","doi-asserted-by":"crossref","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs \u2013 overview and meta-analyses. J Hypertens. 2015;33:1321\u201341.","DOI":"10.1097\/HJH.0000000000000614"},{"key":"498_CR27","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1097\/HJH.0000000000001547","volume":"35","author":"C Thomopoulos","year":"2017","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens. 2017;35:2150\u201360.","journal-title":"J Hypertens"},{"key":"498_CR28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/bcpt.13492","volume":"128","author":"P Tveden-Nyborg","year":"2021","unstructured":"Tveden-Nyborg P, Bergmann TK, Jessen N, Simonsen U, Lykkesfeldt J. BCPT policy for experimental and clinical studies. Basic Clin Pharmacol Toxicol. 2021;128:4\u20138.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"498_CR29","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1084\/jem.59.3.347","volume":"59","author":"H Goldblatt","year":"1934","unstructured":"Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med. 1934;59:347\u201379.","journal-title":"J Exp Med"},{"key":"498_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/bph.12424","volume":"171","author":"ER Hedegaard","year":"2014","unstructured":"Hedegaard ER, Nielsen BD, Kun A, Hughes AD, Kr\u00f8igaard C, Mogensen S, et al. K V 7 channels are involved in hypoxia-induced vasodilatation of porcine coronary arteries: K V 7 channels in hypoxia-induced dilatation. Br J Pharmacol. 2014;171:69\u201382.","journal-title":"Br J Pharmacol"},{"key":"498_CR31","doi-asserted-by":"crossref","unstructured":"Baumbach GL, Heistad DD. Remodeling of cerebral arterioles in chronic hypertension. Hypertension. 1989;13:968\u201372.","DOI":"10.1161\/01.HYP.13.6.968"},{"key":"498_CR32","doi-asserted-by":"publisher","first-page":"e0117560","DOI":"10.1371\/journal.pone.0117560","volume":"10","author":"Y Li","year":"2015","unstructured":"Li Y, Li X, Huang Z, Yang G, Zhang G, Zhao S, et al. A randomized, double blind, placebo-controlled, multicenter phase II trial of Allisartan Isoproxil in essential hypertensive population at low-medium risk. PloS One. 2015;10:e0117560.","journal-title":"PloS One"},{"key":"498_CR33","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1111\/bph.12805","volume":"171","author":"TA Jepps","year":"2014","unstructured":"Jepps TA, Bentzen BH, Stott JB, Povstyan OV, Sivaloganathan K, Dalby-Brown W, et al. Vasorelaxant effects of novel Kv 7.4 channel enhancers ML213 and NS15370. Br J Pharmacol. 2014;171:4413\u201324.","journal-title":"Br J Pharmacol"},{"key":"498_CR34","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.3892\/mmr.2014.2001","volume":"9","author":"H Zhang","year":"2014","unstructured":"Zhang H, Wu S, Huang C, Li X. Long-term treatment of spontaneously hypertensive rats with losartan and molecular basis of modulating Ito of ventricular myocytes. Mol Med Rep. 2014;9:1959\u201367.","journal-title":"Mol Med Rep"},{"key":"498_CR35","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1161\/01.RES.79.4.669","volume":"79","author":"M Gidh-Jain","year":"1996","unstructured":"Gidh-Jain M, Huang B, Jain P, El-Sherif N. Differential expression of voltage-gated K + channel genes in left ventricular remodeled myocardium after experimental myocardial infarction. Circ Res. 1996;79:669\u201375.","journal-title":"Circ Res"},{"key":"498_CR36","doi-asserted-by":"crossref","unstructured":"Jackson WF. K channels and the regulation of vascular smooth muscle tone. Microcirc. 2018;25:10.1111\/micc.12421","DOI":"10.1111\/micc.12421"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-021-00498-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-021-00498-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-021-00498-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T07:05:33Z","timestamp":1623222333000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-021-00498-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,9]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["498"],"URL":"https:\/\/doi.org\/10.1186\/s40360-021-00498-7","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,9]]},"assertion":[{"value":"25 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental protocols were approved by the Institutional Animal Care and Use Committee of Shanghai Jiao Tong University (Shanghai, China) and the Ethics Committees of Shanghai Jiao Tong University. All experiments were performed in accordance to relevant guidelines and regulations in the Care and Use of Laboratory Animals. The study was conducted in accordance with the Basic & Clinical Pharmacology & Toxicology policy for experimental and clinical studies. The study was carried out in compliance with the ARRIVE guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}